Novelion Therapeutics Inc.

Equities

NVLNF

CA67001K2020

Delayed OTC Markets Other stock markets			5-day change	1st Jan Change
- ^USD	-.--%		-4.49%	-0.54%

2022	Novelion Therapeutics Inc. Announces Final Cash Distribution, Payable on or About March 31, 2022	CI
2020	Novelion Therapeutics Inc. Announces Management Changes	CI

Novelion Therapeutics Inc. Appoints Murray Stewart as Executive Vice President and Head of R&D, Effective November 27, 2017

October 12, 2017 at 02:15 pm

Novelion Therapeutics Inc. announced the appointment of Murray Stewart, M.D. as Executive Vice President and Head of R&D, effective November 27, 2017. Dr. Stewart will join the company from GlaxoSmithKline (GSK) where he is currently chief medical officer.

Latest news about Novelion Therapeutics Inc.

Novelion Therapeutics Inc. Announces Final Cash Distribution, Payable on or About March 31, 2022	29/03/22	CI
Novelion Therapeutics Inc. Announces Management Changes	17/01/20	CI
Novelion Therapeutics Inc. Announces Management Changes	03/01/20	CI
Declaration of Voting Results by Novelion Therapeutics Inc.	05/11/19	CI
Declaration of Voting Results by Novelion Therapeutics Inc.	05/11/19	CI
Novelion Therapeutics Inc.(OTCPK:NVLN.F) dropped from NASDAQ Composite Index	08/10/19	CI
Novelion Therapeutics Provides Information to Shareholders	04/10/19	CI
Novelion Therapeutics Provides Information to Shareholders	04/10/19	CI
Novelion Therapeutics Inc. Provides Information to the Shareholders	03/10/19	CI
Novelion Therapeutics Inc. Provides Information to the Shareholders	03/10/19	CI
Novelion Therapeutics Inc. Elects Michael D. Price to Serve as a Director	03/10/19	CI
Novelion Therapeutics Inc. Announces Management Changes	25/09/19	CI
Novelion Therapeutics Provides Information to Shareholders	20/09/19	CI
Novelion Therapeutics Responds to Whitefort Capital Petition	24/06/19	CI
Whitefort Capital Files a Petition Against Novelion Therapeutics	20/06/19	CI
Novelion Therapeutics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2019	07/05/19	CI
Novelion Therapeutics Inc. Provides the Earnings Guidance for the Year 2019	07/05/19	CI
Whitefort Capital Discloses its Views on Novelion Therapeutics	02/04/19	CI
Novelion Therapeutics Inc. Auditor Raises 'Going Concern' Doubt	14/03/19	CI
Novelion Therapeutics Inc. Provides Revenue Guidance for the Year 2019	14/03/19	CI
Novelion Therapeutics Inc. Announces Unaudited Consolidated Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2018	14/03/19	CI
Healthcare Value Urges Novelion To Explore Strategic Alternatives	04/12/18	CI
Novelion Is Considering Multiple Strategic Alternatives	04/12/18	CI
Healthcare Value Pushes Novelion Therapeutics to Explore Strategic Alternatives	03/12/18	CI
Novelion Therapeutics Inc. Announces Executive Changes	20/11/18	CI

Chart Novelion Therapeutics Inc.

Duration

Period

More charts

Company Profile

Novelion Therapeutics Inc, formerly QLT Inc., is a Canada-based biopharmaceutical company. The Company is engaged in development of new standards of care for individuals living with rare diseases. The Company is focused on advancing its portfolio of rare disease therapies by investing in science and clinical development. The Company holds a portfolio of products through its subsidiary, Aegerion Pharmaceuticals, Inc., a biopharmaceutical company dedicated to the development and commercialization of innovative therapies for patients with debilitating rare diseases. The Company's portfolio of products include MYALEPT and JUXTAPID. The Company is also developing zuretinol acetate for the treatment of inherited retinal disease caused by underlying mutations in RPE65 or LRAT genes.

Sector

More about the company